Fate Therapeutics Q1 cash $272.7M; FT819 gets RMAT designation for SLE

FATE THERAPEUTICS INC

Cash, equivalents, and investments $272.7M as of March 31, 2025; projected runway through 1H27.
FT819 granted RMAT designation by FDA for moderate-to-severe SLE; new data at EULAR June 11.
Phase 1 study expanded to include AAV, IIM, SSc autoimmune disease cohorts; enrollment ongoing.
Revenue $1.6M from Ono collaboration; total operating expenses $42.9M (R&D $29.1M, G&A $13.8M).
Common shares outstanding 114.6M; preferred shares (convertible 5:1) 2.8M; pre-funded warrants 3.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.